NEW YORK--(BUSINESS WIRE)--TJC LP (“TJC” or “the Firm”), a middle-market private equity firm investing primarily in North America, today announced that the Firm earned the #4 ranking on the HEC ...

The Archdiocese of New York is preparing for a new archbishop for the first time in almost 17 years. "The installation of a bishop is an administrative act, not a sacramental act," explained Hartford ...

TJC LP (“TJC” or “the Firm”), a middle-market private equity firm investing primarily in North America, today announced that the Firm earned the #4 ranking on the HEC Paris-Dow Jones 2025 Global ...

DOWNERS GROVE, Ill., Feb. 4, 2026 /PRNewswire/ -- AllTranstek, LLC, a subsidiary of RAILTRAC Technologies Inc. and affiliate of Bourque Logistics LLC, today announced that it has completed the ...

In Holding Aloft the Banner of Ethiopia, historian Winston James opines that the Caribbean, having produced one of the most mobile African diasporas in modern history, also generated a striking number ...

Downers Grove, Ill.-based AllTranstek LLC has acquired the assets of Darien, Ill.-based RAS Data Services (RAS), following its identification last month as the prevailing auction bidder. AllTranstek, ...

Alex Valdes from Bellevue, Washington has been pumping content into the Internet river for quite a while, including stints at MSNBC.com, MSN, Bing, MoneyTalksNews, Tipico and more. He admits to being ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

BEIJING/HONG KONG, Sept 10 (Reuters) - U.S. investment firm Bain Capital has agreed to sell data centre operator WinTriX DC Group's China business to a consortium led by Guangdong Hec Technology ...

Forbes contributors publish independent expert analyses and insights. Dianne Plummer is an Energy Consultant and Certified Energy Manager. Rooftop solar has become one of the fastest-growing clean ...

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.